Latest Genovis News & Updates

See the latest news and media coverage for Genovis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Genovis

Biotechnology company specializing in protein analysis tools

genovis.com
Headquarters
Kävlinge, Sweden
Founded year
1999
Company type
Public company
Number of employees
40–50

Latest news about Genovis

Company announcements

  • Genovis

    Genovis reports 4% net sales growth for Q1 2026

    Net sales reached SEK 33,506 thousand. EBITDA improved to SEK 9,510 thousand. Launched LysCERATOR™ and SEQguard™. Signed ADC license deal.

  • Genovis

    Genovis summons shareholders to AGM

    The meeting occurs on May 18, 2026, at 5:00 p.m. in Kävlinge. Proposals cover board elections, fees, auditors, remuneration guidelines, and share issue authorizations.

  • Genovis

    Genovis and Plasmidsaurus launch SEQguard™ Dino Preserve

    The product enables ambient-temperature RNA shipping for next-generation sequencing, reducing costs and carbon footprint. It integrates with Plasmidsaurus' workflows.

  • Genovis

    Genovis enters non-exclusive license agreement for EndoS2 technology

    The US biotech licensee gains worldwide rights for ADC research, development, and commercialization. Genovis receives upfront and milestone payments up to USD 20 million per program.

Unlock all announcements with a

Media coverage

  • TradingView

    Genovis AB publishes Annual Report 2025 — TradingView News

    Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and...

  • The Scientist

    Plasmidsaurus Accelerates RNA-Seq: New EU Hub and Genovis Partnership Adds Stability to Speed, Without the Ice

    Plasmidsaurus, the leading Sequencing as a Service company, has announced two transformative evolutions of its RNA-Seq ecosystem: the launch of a high-capacity RNA sequencing hub...

  • Affärsvärlden

    Affärsvärlden gives buy recommendation for Genovis

    Affärsvärlden gives buy recommendation for the biotech company Genovis in an analysis on Thursday.

  • London Stock Exchange

    Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization

    Genovis AB announces that it has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ proprietary...

Unlock all articles with a

Never miss news about Genovis

Track Genovis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Genovis competitors & trending companies

Browse news for competitors to Genovis and other trending companies.